[{"id":"b7618037-1369-4803-9a4d-36cc465a98d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159906","created_at":"2025-09-13T08:44:39.729Z","updated_at":"2025-09-13T08:44:39.729Z","phase":"Phase 1/2","brief_title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT07159906","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/08/2025","start_date":" 09/08/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-09-08"},{"id":"893adf5f-401b-45ed-b55a-95592085576f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04874194","created_at":"2021-05-05T11:52:46.095Z","updated_at":"2024-07-02T16:35:02.356Z","phase":"Phase 1/2","brief_title":"Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1","source_id_and_acronym":"NCT04874194","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RUNX1","pipe":" | ","alterations":" RUNX1 mutation","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-21"},{"id":"a40edb33-4956-4fcb-af35-db7081c0b606","acronym":"","url":"https://clinicaltrials.gov/study/NCT06328179","created_at":"2024-03-25T17:36:14.935Z","updated_at":"2024-07-02T16:35:12.972Z","phase":"","brief_title":"Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.","source_id_and_acronym":"NCT06328179","lead_sponsor":"Huai'an First People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-03-25"},{"id":"1ba19375-a278-4a1e-94fc-7fcdc21b85ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05100251","created_at":"2021-10-29T13:53:09.517Z","updated_at":"2024-07-02T16:35:57.046Z","phase":"Phase 1","brief_title":"Clinical Trial of WB100 on Advanced Solid Tumor","source_id_and_acronym":"NCT05100251","lead_sponsor":"Zhejiang University","biomarkers":" MYC • CA 19-9","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC positive","tags":["MYC • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WB100"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 10/25/2023","primary_completion_date":" 10/25/2023","study_txt":" Completion: 10/25/2023","study_completion_date":" 10/25/2023","last_update_posted":"2023-01-26"},{"id":"1fd7db54-93ac-41e4-bc56-3603227c89e8","acronym":"ROCKET","url":"https://clinicaltrials.gov/study/NCT02096354","created_at":"2021-01-18T09:40:38.201Z","updated_at":"2024-07-02T16:36:10.444Z","phase":"Phase 2","brief_title":"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02096354 - ROCKET","lead_sponsor":"EpicentRx, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • irinotecan • nibrozetone (RRx-001)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/13/2018","primary_completion_date":" 04/13/2018","study_txt":" Completion: 04/13/2018","study_completion_date":" 04/13/2018","last_update_posted":"2022-05-16"},{"id":"3dc09b40-82a5-425d-b8e9-5b1b7d8b100e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00462943","created_at":"2021-12-28T22:53:39.815Z","updated_at":"2024-07-02T16:36:19.138Z","phase":"Phase 2","brief_title":"Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML","source_id_and_acronym":"NCT00462943","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Synribo (omacetaxine mepesuccinate)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 03/07/2007","start_date":" 03/07/2007","primary_txt":" Primary completion: 08/04/2009","primary_completion_date":" 08/04/2009","study_txt":" Completion: 06/27/2013","study_completion_date":" 06/27/2013","last_update_posted":"2021-12-28"},{"id":"e42a85e3-8a8f-4ba5-b42b-6faaef554669","acronym":"","url":"https://clinicaltrials.gov/study/NCT00375219","created_at":"2021-11-11T18:45:16.493Z","updated_at":"2024-07-02T16:36:20.742Z","phase":"Phase 2","brief_title":"Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation","source_id_and_acronym":"NCT00375219","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Synribo (omacetaxine mepesuccinate)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 09/20/2006","start_date":" 09/20/2006","primary_txt":" Primary completion: 03/23/2010","primary_completion_date":" 03/23/2010","study_txt":" Completion: 06/28/2013","study_completion_date":" 06/28/2013","last_update_posted":"2021-11-15"},{"id":"bf75e380-cf06-45ab-9526-c6dc47a6700e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04505995","created_at":"2021-01-18T21:36:19.252Z","updated_at":"2024-07-02T16:36:42.207Z","phase":"","brief_title":"Azacitidine and Homoharringtonine in JMML","source_id_and_acronym":"NCT04505995","lead_sponsor":"Fourth Military Medical University","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2020-08-10"}]